Zosurabalpin (Synonyms: Abx MCP; RG6006) |
Katalog-Nr.GC75345
One-Click Copy Product Info
|
Zosurabalpin is a novel class of tethered macrocyclic peptide antibiotics active against various Acinetobacter baumannii complex (ABC) isolates with the MIC90 values of 0.06-0.5mg/L.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2379336-76-0
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Zosurabalpin is a novel class of tethered macrocyclic peptide antibiotics active against various Acinetobacter baumannii complex (ABC) isolates with the MIC90 values of 0.06-0.5mg/L [1]. Zosurabalpin disrupts the transport of lipopolysaccharide (LPS) by inhibiting the LptB2FGC protein complex, which causes LPS to accumulate to toxic levels inside the cell, ultimately resulting in bacterial death[2]. Zosurabalpin has been widely used to inhibit the proliferation of drug-resistant bacteria in animal models[3].
In vivo, Zosurabalpin treatment via subcutaneous injection at a dose of 60mg/kg every 6 hours for 24 hours significantly reduced bacterial burden and improved survival in a mouse model of A. baumannii-induced pneumonia[4].
References:
[1] Arshad N, Azzam W, Zilberberg M D, et al. Acinetobacter baumannii complex infections: new treatment options in the antibiotic pipeline[J]. Microorganisms, 2025, 13(2): 356.
[2] Wang W J, Dong X M, Li G B. Macrocyclic peptides: up-and-coming weapons to combat antimicrobial resistance[J]. Signal Transduction and Targeted Therapy, 2024, 9(1): 81.
[3] Que W, Deng Z, Gao J. Clinical crusade: zosurabalpin's charge against antibiotic resistance[J]. Trends in Molecular Medicine, 2024, 30(5): 420-422.
[4] Zampaloni C, Mattei P, Bleicher K, et al. A novel antibiotic class targeting the lipopolysaccharide transporter[J]. Nature, 2024, 625(7995): 566-571.
| Animal experiment [1]: | |
Animal models | Male CD-1 mice |
Preparation Method | Neutropenia was induced in male CD-1 mice by two consecutive intraperitoneal injections of cyclophosphamide monohydrochloride (CPM) on days -4 and -1, respectively, prior to the initiation of treatment with Zosurabalpin. Approximately 106CFU of bacterial suspension of A. baumannii isolate was injected into each thigh muscle to induce infection, and treatment was started 2h after infection. Zosurabalpin (60mg/kg) was administered subcutaneously every 6 hours. The thigh bacterial burden was determined 24h after treatment. |
Dosage form | 60mg/kg; every 6 hours for 24h; s.c. |
Applications | Zosurabalpin treatment of mice resulted in a remarkable decrease in bacterial burden. |
References: | |
| Cas No. | 2379336-76-0 | SDF | |
| Überlieferungen | Abx MCP; RG6006 | ||
| Formula | C43H50N8O5S | M.Wt | 790.97 |
| Löslichkeit | DMSO: 4.76 mg/mL (6.02 mM; adjust pH to 7 with 1 M HCL) | Storage | -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.2643 mL | 6.3214 mL | 12.6427 mL |
| 5 mM | 252.9 μL | 1.2643 mL | 2.5285 mL |
| 10 mM | 126.4 μL | 632.1 μL | 1.2643 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)